International liver transplantation society consensus statement on hepatitis c management in liver transplant candidates

Transplantation

Volumn 101, Issue 5, 2017, Pages 945-955

  Terrault, Norah A ^a   McCaughan, Geoff W ^b   Curry, Michael P ^c   Gane, Edward ^d   Fagiuoli, Stefano ^e   Fung, James Y Y ^f   Agarwal, Kosh ^g   Lilly, Les ^h   Strasser, Simone I ^b   Brown, Kimberly A ⁱ   Gadano, Adrian ^j   Kwo, Paul Y ^k   Burra, Patrizia ^l   Samuel, Didier ^m   Charlton, Michael ⁿ   Pessoa, Mario G ^o   Berenguer, Marina ^p  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f QUEEN MARY HOSPITAL   (Hong Kong)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h TORONTO GENERAL HOSPITAL   (Canada)

ⁱ HENRY FORD HOSPITAL   (United States)

^j HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^k STANFORD UNIVERSITY   (United States)

^l UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ Utah Intermountain Transplant and Regenerative Medicine Center   (United States)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR;

CHOLESTATIC HEPATITIS; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE COURSE; DISEASE SEVERITY; HEALTH CARE PERSONNEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; MEDICAL SOCIETY; MIXED INFECTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPLICATION; DONOR; DRUG ADMINISTRATION; END STAGE LIVER DISEASE; HOSPITAL ADMISSION; LIVER TUMOR; PRACTICE GUIDELINE; PREOPERATIVE CARE; PROCEDURES; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PREOPERATIVE CARE; TISSUE DONORS; WAITING LISTS;

EID: 85014079544     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001708     Document Type: Review

References (62)

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
2. Terrault N, Berenguer M, Strasser S, et al. International Liver Transplantation Society Consensus Statement on Hepatitis C management in liver transplant recipients. Transplantation. 2017;101:956-967.
3. KimWR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686.
4. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a metaanalysis of observational studies. Ann Intern Med. 2013;158:329-337.
5. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
6. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217-1223.
7. Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015; 62:79-86.
8. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370: 1973-1982.
9. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
10. Poordad F, Schiff E, Vierling J, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493-1505.
11. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373: 2618-2628.
12. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752-1762.
13. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255-262.
14. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100-107. e1.
15. AASLD/IDSA/AS-USA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Volume 2016, 2016.
16. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
17. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236.
18. Coilly A, Pageaux G, Houssel-Debry P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs? Hepatology. 2015;62. Abstract 95.
19. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
20. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with directacting antivirals. J Hepatol. 2016;65:727-733.
21. Piovesan S, Anastassopoulos G, Alberti A, et al. Incidence and pattern of de novo hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology. 2016. Abst A19.
22. Pol S. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734-740.
23. Elliot B, Tapper E, Afdhal N, et al. Before or after transplantation? A review of the cost effectiveness of treating waitlisted patients with Hepatitis C. Transplantation. 2017;101:933-937.
24. Salazar J, Saxena V, Kahn J, et al.Cost-effectiveness of direct-acting anti-viral treatment in hepatitis C-infected liver transplant candidates with compensated cirrhosis and hepatocellular carcinoma. [published online December 6, 2017]. Transplantation. doi: 10.1097/TP.0000000000001605.
25. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
26. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224-1231.
27. Welzel TM, Petersen J, Herzer K, et al. Erratum: daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:2060.
28. Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741-747.
29. Afdhal N, Asselah T, Everson GT, et al. HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. EASL, 2016 Barcelona April 22-24 2016: LBP-518.
30. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524-531.
31. Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017; 65:777-788.
32. Ahmed A, Gonzalez SA, Cholankeril G, et al. Treatment of patients waitlisted for liver transplant with an all-oral DAAs is a cost-effective treatment strategy in the United States. [published ahead of print March 3, 2017] Hepatology. doi: 10.1002/hep.29137.
33. Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692-699.
34. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.
35. Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2016. doi: 10.1093/ndt/gfw348.
36. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-726.
37. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866-1876.
38. Roche B, Belnard M, Pham P, et al. Prospective assessment of liver fibrosis after liver transplantation in HIV/HCV coinfected patients: a useful tool assessing severe fibrosis on the liver graft. J Hepatol. 2012;56: S93-S93.
39. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983-2993.
40. Miro JM, Stock P, Teicher E, et al. Outcome and management of HCV/HIV coinfection pre-and post-liver transplantation. A 2015 update. J Hepatol. 2015;62:701-711.
41. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138:159-164.
42. Stock PG, Terrault NA. Human immunodeficiency virus and liver transplantation: hepatitis C is the last hurdle. Hepatology. 2015;61:1747-1754.
43. Londono M, Manzardo C, Rimola A, et al. IFN-free therapy for HIV/HCVcoinfected patients within the liver transplant setting. J Antimicrob Chemother. 2016;71:3195-3201.
44. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-789.
45. Bowring MG, Kucirka LM, Luo X, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17:519-527.
46. Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91: 1265-1272.
47. O'Leary JG, Neri MA, Trotter JF, et al. Utilization of hepatitis C antibodypositive livers: genotype dominance is virally determined. Transpl Int. 2012;25:825-829.
48. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149-153.
49. Suryaprasad A, Basavaraju SV, Hocevar SN, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant. 2015;15:1827-1835.
50. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001;7: 762-768.
51. Ricchiuti A, Brunati A, Mirabella S, et al. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569-2570.
52. Northup P, Argo C, Nguyen D, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038-1044.
53. Burr AT, Li YF, Tseng JF, et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011;35:1590-1595.
54. Alvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from antihepatitis C virus-positive donors: our experience. Transplant Proc. 2012; 44:1475-1478.
55. Lai JC, O'Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18:532-538.
56. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl. 2006;12:1496-1503.
57. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73: 582-587.
58. Torres M, Weppler D, Reddy KR, et al. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology. 1999;117:1253.
59. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925-929.
60. Saab S, Chang A, Comulada S, et al. Outcomes of hepatitis C-and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9:1053-1061.
61. Willuweit K, Canbay A, Gerken G, et al. Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation. Minerva Gastroenterol Dietol. 2017; 63:55-61.
62. Hundemer GL, Sise ME,Wisocky J, et al. Use of sofosbuvir-based directacting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47:924-929.